Tags

Type your tag names separated by a space and hit enter

Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
J Postgrad Med. 2013 Jul-Sep; 59(3):226-8.JP

Abstract

We report two cases, one male (33 years) and a female (14 years), that developed Post-Kala-azar Dermal Leishmaniasis (PKDL) after successful treatment for visceral leishmaniasis (VL) or Kala-azar with AmBisome, the lipid complex of Amphotericin B. Both cases presented with hypo-pigmented macular lesions all over the body. The patients responded well to AmBisome after treatment with three courses. This first ever case report from India indicates that possibly there is no effective drug for VL until date, which can prevent post-treatment development of PKDL.

Authors+Show Affiliations

Department of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

24029204

Citation

Das, V N R., et al. "Development of Post-kala-azar Dermal Leishmaniasis in AmBisome Treated Visceral Leishmaniasis: a Possible Challenge to Elimination Program in India." Journal of Postgraduate Medicine, vol. 59, no. 3, 2013, pp. 226-8.
Das VN, Pandey K, Singh D, et al. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India. J Postgrad Med. 2013;59(3):226-8.
Das, V. N., Pandey, K., Singh, D., Forwood, C., Lal, C. S., & Das, P. (2013). Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India. Journal of Postgraduate Medicine, 59(3), 226-8. https://doi.org/10.4103/0022-3859.118046
Das VN, et al. Development of Post-kala-azar Dermal Leishmaniasis in AmBisome Treated Visceral Leishmaniasis: a Possible Challenge to Elimination Program in India. J Postgrad Med. 2013 Jul-Sep;59(3):226-8. PubMed PMID: 24029204.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India. AU - Das,V N R, AU - Pandey,K, AU - Singh,D, AU - Forwood,C, AU - Lal,C S, AU - Das,P, PY - 2013/9/14/entrez PY - 2013/9/14/pubmed PY - 2014/6/5/medline SP - 226 EP - 8 JF - Journal of postgraduate medicine JO - J Postgrad Med VL - 59 IS - 3 N2 - We report two cases, one male (33 years) and a female (14 years), that developed Post-Kala-azar Dermal Leishmaniasis (PKDL) after successful treatment for visceral leishmaniasis (VL) or Kala-azar with AmBisome, the lipid complex of Amphotericin B. Both cases presented with hypo-pigmented macular lesions all over the body. The patients responded well to AmBisome after treatment with three courses. This first ever case report from India indicates that possibly there is no effective drug for VL until date, which can prevent post-treatment development of PKDL. SN - 0972-2823 UR - https://www.unboundmedicine.com/medline/citation/24029204/Development_of_post_kala_azar_dermal_leishmaniasis_in_AmBisome_treated_visceral_leishmaniasis:_a_possible_challenge_to_elimination_program_in_India_ L2 - http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2013;volume=59;issue=3;spage=226;epage=228;aulast=Das DB - PRIME DP - Unbound Medicine ER -